Form 4: Hologic Merger Completes, Executive Ownership Changes

Jennifer M. Schneiders reports on changes in beneficial ownership following Hologic Inc.'s merger, with stock options and performance units converted to cash and contingent value rights.

Summary

• Jennifer M. Schneiders, President of Diagnostic Solutions at Hologic Inc., has filed a Form 4 detailing changes in her beneficial ownership of company securities.
• These changes are a result of Hologic's merger with Hopper Parent Inc. and Hopper Merger Sub Inc., effective April 7, 2026.
• As part of the merger, each share of Hologic common stock was converted into $76.00 in cash plus one contingent value right (CVR) potentially worth up to $3.00.
• Schneiders' outstanding stock options were cancelled and converted into cash payments or CVRs, depending on their exercise price relative to the merger consideration.
• Performance stock units (PSUs) were also converted into the right to receive the merger consideration, with performance goals deemed achieved at the greater of target or actual levels.
• Following the merger, Schneiders no longer beneficially owns any shares of Hologic common stock directly or indirectly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily reporting on the mechanics of executive compensation conversion following a completed merger, rather than providing new operational or financial performance data.

Positives

• The merger was successfully completed, providing shareholders with cash consideration and contingent value rights.
• Executive stock options and performance units were converted into value, reflecting the terms of the merger agreement.
• The filing indicates a clear process for valuing and converting executive equity awards in the context of the acquisition.

Negatives

• The filing confirms the delisting of Hologic common stock as a result of the merger.
• Certain stock options with exercise prices at or above the total merger consideration ($79.00) were cancelled for no value.

Risks

• The value of the contingent value rights (CVRs) is not guaranteed and depends on future performance or events, introducing uncertainty for former shareholders and executives.
• The conversion of equity awards may have tax implications for the reporting person.

Future Outlook

The future outlook for Hologic is now tied to the performance of the acquiring entity and the realization of value from the contingent value rights (CVRs). Specific future financial guidance is not provided in this Form 4 filing.

Management Comments

• The filing details the conversion of stock options and performance stock units into cash and contingent value rights as per the merger agreement.
• It is noted that performance goals for PSUs were deemed achieved at the greater of target or actual levels through the latest practicable date prior to the merger's effective time.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects a common outcome for executives in a company acquisition scenario, where equity awards are converted into cash or contingent rights based on the deal terms. The structure of the merger consideration, including a cash component and a CVR, is a prevalent strategy in M&A to bridge valuation gaps and incentivize continued performance post-transaction.

Stakeholder Impact

• Shareholders: Received cash and CVRs, with the ultimate value of CVRs dependent on future performance.
• Employees: Executive compensation structures were converted as per the merger agreement.
• Management: Jennifer M. Schneiders' beneficial ownership of Hologic stock has been converted into cash and CVRs.

Next Steps

• Former Hologic shareholders and executives will await the determination and potential payout of the Contingent Value Rights (CVRs).
• The reporting person will no longer be subject to Section 16 reporting for Hologic Inc. common stock.

Key Dates

Keywords

Hologic Inc., HOLX, Form 4, Merger, Acquisition, Beneficial Ownership, Stock Options, Performance Stock Units, Contingent Value Rights, Jennifer M. Schneiders, SEC Filing